(89) Zr-rituximab PET/CT to detect neurolymphomatosis

Am J Hematol. 2016 Jun;91(6):649-50. doi: 10.1002/ajh.24328. Epub 2016 Apr 13.

Authors

Antoinette de Jong¹, Rogier Mous², Guus A M S van Dongen³, Otto S Hoekstra³, Rutger A J Nievelstein¹, Bart de Keizer¹

Affiliations

¹ Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
² Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
³ Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.

PMID: 26872558
DOI: 10.1002/ajh.24328

No abstract available

Publication types

Case Reports

MeSH terms

Animals
Antibodies, Monoclonal, Murine-Derived*
Biopsy
Female
Fluorodeoxyglucose F18
Humans
Lymphoma, Large B-Cell, Diffuse / complications
Lymphoma, Large B-Cell, Diffuse / drug therapy
Marek Disease / diagnosis*
Marek Disease / drug therapy
Marek Disease / etiology
Middle Aged
Phenotype
Positron Emission Tomography Computed Tomography* / methods
Rituximab

Substances

89Zr-rituximab
Antibodies, Monoclonal, Murine-Derived
Fluorodeoxyglucose F18
Rituximab